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Abstract
Background: HIV-associated neurocognitive disorders (HAND) are a major complication in at least half of the
infected population despite effective antiretroviral treatment and immune reconstitution. HIV-associated CNS
damage is not correlated with active viral replication but instead is associated with mechanisms that regulate
inflammation and neuronal compromise. Our data indicate that one of these mechanisms is mediated by gap
junction channels and/or hemichannels. Normally, gap junction channels shutdown under inflammatory conditions,
including viral diseases. However, HIV infection upregulates Connexin43 (Cx43) expression and maintains gap
junctional communication by unknown mechanism(s).
Methods: Human primary astrocytes were exposed to several HIV proteins as well as to HIV, and expression and
function of Connexin43- and Connexin30-containing channels were determined by western blot, immunofluorescence,
microinjection of a fluorescent tracer and chromatin immunoprecipitation (ChIP).
Results: Here, we demonstrate that HIV infection increases Cx43 expression in vivo. HIV-tat, the transactivator of the
virus, and no other HIV proteins tested, increases Cx43 expression and maintains functional gap junctional
communication in human astrocytes. Cx43 upregulation is mediated by binding of the HIV-tat protein to the
Cx43 promoter, but not to the Cx30 promoter, resulting in increased Cx43 messenger RNA (mRNA) and
protein as well as gap junctional communication.
Conclusions: We propose that HIV-tat contributes to the spread of intracellular toxic signals generated in a
few HIV-infected cells into surrounding uninfected cells by upregulating gap junctional communication. In the
current antiretroviral era, where HIV replication is often completely suppressed, viral factors such as HIV-tat are
still produced and released from infected cells. Thus, blocking the effects of HIV-tat could result in new
strategies to reduce the damaging consequences of HIV infection of the CNS.
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Background
HIV enters the CNS early after infection, and CNS viral
persistence results in many neurological abnormalities
[1, 2]. As the prevalence of HIV-associated neurocogni-
tive disorders (HAND) increases [2, 3], understanding
the mechanisms mediating the pathogenesis of HAND
becomes even more critical. Currently, there is no correl-
ation between the low to undetectable levels of HIV repli-
cation and extensive CNS damage. Therefore, several
groups suggested that this damage is due to amplification
systems used by the virus to increase HIV-associated in-
flammation. We propose that connexin (Cx)-containing
gap junctions (GJ) and hemichannels (HC) are important
in the amplification of this disease process.
Gap junctions are aggregates of channels connecting the
cytoplasmic compartments of the coupled cells and provide
direct continuity between the cells allowing electrical and
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metabolic coordination [4, 5]. A GJ channel is formed by the
docking of two hemichannels (one contributed by each of
the joined cells), and each hemichannel is composed of six
protein subunits termed connexins (Cx). Recent evidence
indicates that hemichannels composed of Cx in non-
junctional membranes can open to the extracellular space
under appropriate conditions and allow diffusional ex-
change between the cytoplasmic compartment and the
extracellular environment, including highly inflammatory
factors such as ATP, glutamate, and prostaglandins [4, 5].
Astrocytes are the most abundant cell type in the CNS
and are highly coupled by gap junctions containing
Cx43 and Cx30 to coordinate metabolic and electric
events [5], and only recently, there is increasing evidence
of their significance in HIV infection. Despite their low
viral replication and percentage of HIV-infected astro-
cytes present in vivo and in vitro (5 to 19 %), significant
changes in astrocyte gene expression [6], apoptosis [7–10],
glutamate metabolism, and blood brain barrier (BBB) [7, 8]
have been reported, suggesting that these cells play a key
role in NeuroAIDS.
Our laboratories demonstrated that despite low repli-
cation and numbers of HIV-infected astrocytes, Cx con-
taining channels, including gap junctions and
hemichannels, allow toxins from these few HIV-infected
astrocytes to reach neighboring uninfected CNS cells
[4, 7, 8, 11]. In our studies, it was surprising that con-
nexin channels in human astrocytes are maintained or
increased in response to HIV infection. Generally, Cx
expression and gap junctional communication are de-
creased under inflammatory conditions, including viral
infections [4, 12]. However, HIV infection of astrocytes
results in opening of hemichannels, increased Cx43 ex-
pression, and maintenance of gap junctional communi-
cation [4, 7, 8, 11]. In this report, we demonstrate that
expression of Cx43, but not of Cx30, is upregulated in
HIV-infected conditions, especially in tissues obtained
from HIV-infected individuals with cognitive impair-
ment. In addition, we demonstrate that HIV-tat protein
binds to the Cx43 promoter, resulting in an increase in
Cx43 mRNA and protein expression as well as in the
maintenance of gap junctional communication. Our re-
sults of the maintenance of Cx43 expression may explain
how few HIV-infected astrocytes spread intracellular
toxic signals into surrounding uninfected cells.
Methods
Materials
DMEM, fetal bovine serum (FBS), penicillin/strepto-
mycin (P/S), and trypsin-EDTA were from Invitrogen
(Grand Island, NY). Monoclonal antibody to GFAP,
FITC or Cy3- conjugated anti-rabbit IgG, and Cy3 or
FITC-coupled anti-mouse IgG antibodies were from
Sigma (St. Louis, MO). Purified mouse IgG2B and IgG1
myeloma proteins were from Cappel Pharmaceuticals,
Inc. Lipofectamine 2000; anti-connexin43 antibody; anti-
connexin30 antibody; and secondary antibodies anti-
mouse, anti-rabbit, and anti-goat immunoglobulins
conjugated to Alexa-533, Alexa-633, and Alexa-588 were
from Life Technologies (Eugene, OR). Small interfering
RNA (siRNA) for Cx30 and controls were from Santa
Cruz Biotechnology (Santa Cruz, CA). HIV recombinant
proteins, vif, nef, rev, gag (p55, p24, and p7), polymerase,
and gp120 as well as HIVADA and HIVJR-CSF were from
the NIH repository (Germantown, MD). HIV-tat protein
was purchased from the University of Kentucky or was a
gift from Dr. Avindra Nath (NINDS, NIH, MD). We se-
lected concentrations from 1 to 300 ng/ml due to the ef-
fects on neuronal toxicity (100 ng/ml induces neuronal
apoptosis in 50–80 % of the cells and lower concentra-
tions induce minimal apoptosis, 10–20 % [13, 14]). In
addition, HIV-tat induced chemotaxis was also maximal
at 100 ng/ml [15]. Concentrations below 100 ng/ml only
induced minimal microglia migration. Thus, the concen-
trations selected (1 to 300 ng/ml) are appropriate in dif-
ferent models.
Brain tissue sections
Human brain tissue sections (10 to 20 μm) were obtained
from the National NeuroAIDS Tissue Consortium (NNTC).
This consortium is a NIH-funded (U24MH100925) source
to explore the devastating consequences of HIV infection
(www.nntc.org).
Human astrocyte cultures and HIV infection
Cortical human fetal tissue was obtained as part of a re-
search protocol approved by the Albert Einstein College of
Medicine and Rutgers University. The astrocyte cultures
were prepared as previously described and were obtained
from either gender [7, 16]. Confluent cultures of human
astrocytes were infected by incubation with viral stocks
(20–50 ng p24/ml/1 × 106 cells), HIVADA or HIVJR-CSF,
using a previously described protocol [7, 8, 13].
Cx30 siRNA
Three unique 29mer siRNA duplexes to human Cx30 were
designed and obtained from Origene (Rockville, MD).
siRNA (10 nM) transfection was performed with Oligofec-
tamine (Invitrogen) according to the Origene application
guide for Trilencer-29 siRNA. Minimal cell death was de-
tected after transfection. Experiments were performed
2 days post transfection.
Immunofluorescence
Astrocytes were grown on coverslips, fixed, and perme-
abilized in 70 % ethanol for 20 min at −20 °C. Cells were
incubated in blocking solution for 30 min at room
temperature and then in diluted primary antibody (anti-
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HIV-p24, anti-Cx43, anti-Cx30, and anti-GFAP; 1:50,
1:2000, 1:300, and 1:800, respectively) overnight at 4 °C.
Cells were washed several times with PBS at room
temperature and incubated with the appropriate second-
ary antibodies for at least 3 h at room temperature
followed by another wash in PBS for 1 h. Cells were ex-
amined by confocal microscopy using an A1 confocal
microscope (Nikon, Japan). Antibody specificity was
confirmed by replacing the primary antibody with a
non-specific myeloma protein of the same isotype or
non-immune serum as we previously described [17, 18].
Immunofluorescent and confocal microscopy analysis of
human brain tissue samples
Postmortem human brain tissue sections from unin-
fected controls (four cases) and HIV-infected individuals
with HIV encephalitis (HIVE, four cases) and minor cog-
nitive disease (five cases) were analyzed by four color
immunohistochemical staining for DAPI (nuclei stain-
ing), HIV-p24 (HIV viral protein), Cx43 or Cx30, and
GFAP (an astrocyte marker). Sections of 10 μm were
deparaffinized, underwent antigen retrieval, and blocked
(5 mM EDTA, 1 % fish gelatin, 1 % essentially Ig-free
BSA, 2 % human serum, and 2 % horse serum) for
60 min at room temperature and then incubated with
anti-HIV-p24 (HIV viral protein), Cxs, and GFAP (an
astrocyte marker) overnight at 4 °C. The sections were
washed with PBS, incubated with secondary antibodies
for 1 h at room temperature, followed by serial washes
in PBS for 1 h. The samples were then mounted using
Prolong Gold anti-fade reagent (Invitrogen) and examined
by confocal microscopy. Specificity was confirmed by re-
placing the primary antibody with the appropriate isotype-
matched control reagent, anti-IgG2A, or the IgG fraction
of normal rabbit serum (Santa Cruz, Biotechnology).
Western blot
Relative levels of Cx43, Cx30, and tubulin were deter-
mined by immunoblot as described [13, 19]. Astrocyte
cultures were treated with HIV- tat or vehicle and har-
vested in Tris buffer, 10 mM pH 7.4, containing protease
and phosphatase inhibitors (20 mM; pyrophosphate,
20 mM; NaF, 100 mM; NaVO3, 200 μM; leupeptin,
500 μg/ml; aprotinin, 40 μg/ml; soybean trypsin inhibi-
tor, 2 mg/ml; benzamidine, 1 mg/ml; ω-amino caproic
acid, 1 mg/ml; PMSF, 3 mM; and EDTA, 20 mM) [13, 19].
Cells were lysed, and the protein content of each cell
lysate was determined using Bradford’s method [20]
(Bio-Rad labs, Hercules, CA). Samples containing 20 μg of
protein were used to analyze Cx43, Cx30, and tubulin.
Proteins were separated in 7.5 % SDS-PAGE and electro-
phoretically transferred to nitrocellulose, which was then
incubated sequentially with blocking solution (5 % non-fat
milk in Tris-buffered saline); affinity-purified rabbit
polyclonal antibodies prepared against Cx43, Cx30, and
tubulin (1:2000, 1:500, and 1:2000, respectively); and anti-
rabbit IgG conjugated to HRP. Antigen-antibody com-
plexes were detected by ECL (Perkin Elmer, Boston, MA)
and the resulting immunoblot signals were scanned, and
densitometric analysis was performed using NIH-image
software. All results were normalized to the values ob-
tained for control conditions.
Dye coupling
To evaluate the function of gap junction channels, the
intercellular transfer of Lucifer Yellow (LY) (5 % w/v in
150 mM LiCl) was evaluated by microinjecting the dye
into a single cell and evaluating the diffusion of the dye
into neighboring cells, as previously described [21]. Cells
were scored as coupled if dye transfer occurred to one
or more adjacent cells. Dye transfer was evaluated using
a fully motorized Zeiss Z1 microscope. Four independ-
ent experiments were performed in which a minimum
of 20 cells were microinjected per experiment. The inci-
dence and index of dye coupling was scored as the per-
centage of injections that resulted in dye transfer and
the numbers of cells coupled to a single microinjected
cell.
Chromatin immunoprecipitation
Primary human astrocytes were transfected with
pcDNA3.1+/tat101-flag (NIH repository, 10453) with
Lipofectamine 2000. Twenty-four hours post transfec-
tion, chromatin immunoprecipitation (ChIP) analysis
was performed for Cx43 and Cx30. In brief, cells
were fixed and cross-linked using 1 % formaldehyde
and washed in PBS, as we described with minor mod-
ifications [22]. Cells were homogenized, sonicated
until 500-bp fragments were obtained using 20 pulses
of 30 s on and 30 s off in a Microtip (Misonix, Inc,
Microson XL-2000). Samples were pre-cleared with
protein A/G and immunoprecipitated using anti-
FLAG antibodies (Sigma). Specific binding of HIV-tat
to Cx43 and Cx30 promoters was analyzed by qRT-
PCR using a StepOnePlus Real Time PCR system
(Life Technologies) and absolute blue QPCR SYBR
low Rox Mix (Life Technologies). Single product amp-
lification was confirmed by melting curve analysis,
and primer efficacy was near or close to 100 % in all
experiments. The human Cx43 promoter forward pri-
mer 5′-CCT CCT CCC AGT TGA GTC AG-3′ and
reverse primer 5′-ACG CCA AGT GAT TGA ACT
CC-3′ were described previously [23]. Human Cx30
promoter was analyzed using the following primers:
forward 5′-TCC TGC ACT CCT TGC TCC TCA-3′
and reverse 5′-TCC CAC CTG CTG CGC CTT T
[24].
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HIV-p24 ELISA
HIV-p24 concentrations in the medium of uninfected and
HIV-infected cultures were determined by ELISA using a
commercial kit from Perkin Elmer (Boston, MA).
Statistical analysis
Mean differences were tested by non-parametric Kruskal-
Wallis analysis or student’s t test. If a significant F value
was obtained, means were compared with Bonferroni-
Dunn multiple comparison test. A value of p < 0.05 was
considered significant.
Results
Cx43, but not Cx30, is upregulated in human brain tissue
sections obtained from subjects with HIV mild cognitive
disease and encephalitis
To examine the expression levels of astrocytic connexins,
Cx43 and Cx30, we analyzed by immunofluorescence and
subsequent confocal microscopy brain tissue section ob-
tained from uninfected and HIV-infected subjects with
cognitive impairment from the NNTC. Sections obtained
from adult uninfected individuals showed Cx43 and Cx30
mainly localized in GFAP positive astrocytes (Fig. 1, unin-
fected). Confocal analysis of brain sections obtained from
individuals with HIV cognitive impairment and HIV
encephalitis (HIVE) showed increased expression of Cx43
in all astrocytes, especially the one positive for HIV-p24
proteins (Fig. 1, see arrows). In contrast, Cx30 in HIV-
infected individuals was reduced (Fig. 1). No differences in
Cx43 increased levels were detected between mild cogni-
tive and HIVE (data not shown). In addition, GFAP ex-
pression increased and astrocytes become more positive,
suggesting the presence of hypertrophic astrocytes (Fig. 1,
GFAP, HIV). As we reported previously, the percentage of
HIV-p24 positive astrocytes was 5.1 ± 2.15 % [7, 8, 25].
Negative controls using IgGs and control sera did not
show positive staining (data not shown). Thus, HIV infec-
tion increased Cx43 expression in all HIV individuals
analyzed.
HIV-tat protein, but not other HIV proteins, increases
Cx43 expression
Our previous data and the data described above indi-
cate that HIV-infected astrocytes and surrounding cells
have increased expression of Cx43 and gap junctions
remain functional during HIV infection of the CNS
[7, 8] and that HIV infection resulted in the opening of
Cx43-containing hemichannels [26]. These results indi-
cate that despite HIV infection and associated inflam-
mation that normally result in gap junction closure, gap
Fig. 1 Glial expression of Cx43 is upregulated in HIV-infected individuals. Cx43 and Cx30 glial expression was evaluated using human brain tissue
sections obtained from uninfected and HIV-infected individuals with mild and HIVE. Brain sections were evaluated by immunohistochemistry and confocal
microscopy. Astrocyte expression of Cx43 or Cx30 (FITC green) was evaluated using glial fibrillary acid protein (GFAP, an astrocyte marker, red staining) and
HIV infection by staining with HIV-p24 antibodies. In uninfected tissue sections, Cx43 and Cx30 localized in astrocytes (uninfected row). In contrast, in tissues
obtained from HIV-infected individuals, Cx43 was highly upregulated, while Cx30 was downregulated. DAPI staining was used in counter staining. Arrows
represent colocalization of GFAP, Cx43, and HIV-p24. Thus, HIV infection increases Cx43 expression, but not Cx30, in astrocytes
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junctions and hemichannels are present and active. In
other inflammatory and viral diseases, these channels
are shut down [4, 5]. Thus, HIV infection is different.
However, the mechanism(s) by which HIV regulates Cx
expression in human astrocytes were unknown.
To characterize the contribution of specific HIV pro-
teins to the increased Cx43 expression and maintenance
of gap junction communication, we treated uninfected
astrocyte cultures with the HIV (ADA or JR-CSF, R5
strains) for 7, 14, 21, and 28 days or with HIV recom-
binant proteins Vif (1, 100, and 300 ng/ml), Gag (p55,
p24, or p7; 1, 100, and 300 ng/ml), Rev (1, 100, and
250 ng/ml), Nef (1, 100, and 250 ng/ml), gp120 (HIVBal,
HIVJR-CSF, or HIVSF162; 1, 50, and 100 nM), or HIV-tat1–
72 (1, 100, and 300 ng/ml) for 6, 12, 24, and 48 h, and
total expression of Cx43 (Table 1, data from all three
concentrations were combined) and Cx30 (Table 2)
were evaluated by western blot as a screening method.
As a positive control for inflammation and decreased
Cx43 expression, we used human astrocytes treated
with IL-1β (10 ng/ml) as previously described [27].
As we described, human astrocytes can be infected
with both R5 and X4 strains of HIV [7, 8]. In agreement
with other groups [10], low viral replication was de-
tected 7, 14, 21, and 28 days post viral exposure to
HIV92UG021 (X4), HIVJR-CSF (R5), or HIVADA (R5) [7, 8].
HIV infected a small population of astrocytes (4.7 ±
2.8 %). Viral replication of all viral isolates tested in
these cultures was maximal after 14 days post infection,
as determined by HIV-p24 ELISA, and remained stable
until 28 days (data not represented). Despite observing
increased Cx43 in HIV-infected cells and surrounding
cells (see [8]), no significant differences in Cx43 expres-
sion by western blot analysis was detected, probably
due to the low numbers of HIV-infected cells as
compared to the uninfected cells (see Table 1). The
constancy of Cx43 expression in these cultures con-
trasts to the high expression seen in human brain tissue
(Fig. 1), which shows increase in Cx43 immunolabling
in uninfected as well as infected cells. The greater ex-
pression in the diseased brain is likely to be a result of
the much longer exposure than in the cultured cells.
The difference may be that secreted HIV-tat is acting
on uninfected (Fig. 5). HIV-tat may be a toxic signal
that increases Cx43 expression in uninfected cells and
formation of Cx43 hemichannels that allow excessive
influx of Ca2+ and efflux of essential metabolites. HIV-
tat applied to astrocytes in culture clearly increases
Cx43 expression (Fig. 2).
Furthermore, Cx43 protein expression was not al-
tered by any concentration of recombinant vif, gag, rev,
or nef at any time point examined (Table 1). However,
all gp120 concentrations tested decreased Cx43 expres-
sion by 3 to 9 % (p < 0.005, n =4), suggesting that this
HIV protein is not involved in maintaining or increas-
ing Cx43 expression (Table 1). In contrast, exon 1
(HIV-tat1–72) or both exons (HIV-tat1–101; data not
shown) of HIV-tat resulted in upregulation of Cx43
protein expression at all concentrations and time points
tested (Table 1).
In contrast, HIV infection (ADA and JR-CSF) and
the recombinant proteins vif, nef, and gp120 de-
creased Cx30 protein expression at all concentrations
tested (Table 2). Gag and Rev did not alter Cx30 pro-
tein expression (Table 2). HIV-tat resulted in de-
creased expression of Cx30 at all three concentrations
and times tested (Table 2). These results indicate that
HIV-tat contributes to the maintained or increased
expression of Cx43 but contributes to the reduction
in Cx30 expression.
Table 1 Expression of Cx43 by astrocytes after different HIV treatments
Cx43 expression in astrocytes (percentage of control, n = 5)
Treatment (virus) 7 days 14 days 21 days 28 days
HIVADA (20 ng/ml) No change No change No change No change
HIVJR-CSF (20 ng/ml) No change No change No change No change
Treatment (recombinant proteins) 6 h 12 h 24 h 48 h
Vif (1, 100, and 300 ng/ml) No change No change No change No change
Gag (p55, p24, or p7: 1, 100, and 300 ng/ml) No change No change No change No change
Rev (1, 100, and 250 ng/ml) No change No change No change No change
Nef (1, 100, and 250 ng/ml) No change No change No change No change
Gp120 (1, 50, and 100 nM) −8.6 ± 1.3* −5.4 ± 3.2* −4.1 ± 1.2* −3.1 ± 0.5*
HIV-tat1–72 (1, 100, and 300 ng/ml) 45.1 ± 12.3* 21.3 ± 8* 21.1 ± 2.2* 25.1 ± 2.5*
IL-1β (10 ng/ml) −10.2 ± 5.2* −16 ± 6.89* −61.3 ± 11* −69.9 ± 12.6*
Although we used three different concentrations for each HIV protein, no significant differences were detected among them. Thus, we combined the data from
the three different concentrations
*p ≤ 0.05 (n = 4)
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Table 2 Expression of Cx30 on astrocytes after different HIV treatments
Cx30 expression in astrocytes (percentage of control, n = 3)
Treatment (virus) 7 days 14 days 21 days 28 days
HIVADA (20 ng/ml) −12.3 ± 9.9* −22.5 ± 8.9* −32 ± 9.88* −38.9 ± 7.9*
HIVJR-CSF (20 ng/ml) −28.7 ± 6.8* −32.7 ± 11* −49.8 ± 14.6* −65.5 ± 21.2*
Treatment (recombinant proteins) 6 h 12 h 24 h 48 h
Vif (1, 100, and 300 ng/ml) −3.8 ± 1.06* −5.99 ± 2.3* −8.88 ± 4.5 * −8.98 ± 5.6*
Gag (p55, p24, or p7: 1, 100, and 300 ng/ml) No change No change No change No change
Rev (1, 100, and 250 ng/ml) No change No change No change No change
Nef (1, 100, and 250 ng/ml) −5.3 ± 3.2* −8.6 ± 3.43* −12.7 ± 6.6* −14.9 ± 7.45*
Gp120 (1, 50, and 100 nM) −3.44 ± 2.1* −5.6 ± 5.4* −8.88 ± 4.3* −9.15 ± 3.3*
HIV-tat1–72 (1, 100, and 300 ng/ml) −9.02 ± 3.3* −10.5 ± 5.4* −17.5 ± 3.9* −28.1 ± 11.8*
IL-1β (10 ng/ml) −21.7 ± 8.9* −36.54 ± 9* −51.3 ± 9.3* −52.3 ± 21.5*
Although we used three different concentrations for each HIV protein, no significant differences were detected among them. Thus, we combined the data from
the three different concentrations
*p ≤ 0.05 (n = 4)
Fig. 2 HIV-tat increased mRNA and Cx43 protein expression as well as gap junctional communication in human primary astrocytes. Human primary
astrocytes were treated with recombinant HIV-tat protein (100 ng/ml), and expression and function of Cx43-containing channels were analyzed. a Staining
for the nucleus (DAPI, blue staining, in the insets in the left column), Cx43 (Alexa 488, green staining), and GFAP (an astrocyte marker, Cy3, red staining) in
untreated (control) and HIV-tat-treated conditions (HIV-tat) after 24 h of treatment. The last panel represents the merge of all colors. Bar 75 μm. Arrows
denote gap junction plaques. b qRT-PCR for Cx43 and GAPDH mRNA using untreated (control) and HIV-tat-treated cultures of astrocytes at different
time points (0, 6, 12, 24, and 48 h). No significant differences in mRNA Cx43 expression were detected in control cells (white bars). HIV-tat treatment
increased Cx43 mRNA expression in a time-dependent manner (*p≤ 0.001, n = 4, black bars). c Western blot analysis of Cx43 protein expression in
control and HIV-tat-treated human astrocytes for 6, 12, 24, and 48 h. As a loading control, tubulin was used (tub). As a positive control for Cx43 and its
phosphorylation, mouse astrocytes were used (+). d Dye coupling experiments using Lucifer Yellow (LY) showed that in both control and HIV-tat-
treated cultures, dye spread into neighboring cells was 100 % (images not shown). However, HIV-tat increased the numbers of coupled astrocytes for each
microinjection (*p≤ 0.003, n= 4), indicating increased gap junctional communication
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HIV-tat upregulates Cx43 mRNA and protein as well as
increases gap junctional communication
To determine the mechanism(s) by which HIV-tat in-
creased Cx43 protein expression, we evaluated Cx43
mRNA and protein, as well as gap junctional communica-
tion after HIV-tat treatment. Human astrocyte cultures
were treated with 1, 100, or 300 ng/ml of HIV-tat for 6,
12, 24, and 48 h, and cells were analyzed by confocal mi-
croscopy, qRT-PCR, western blotting, and dye coupling
(Fig. 2, only 100 ng/ml of HIV-tat is shown).
Cx43, GFAP, and nuclear staining, and subsequent
analysis by confocal microscopy, demonstrated that
Cx43 is mostly located in the plasma membrane and the
cytoplasm in control conditions as expected (Fig. 2a,
control). When cells were treated with HIV-tat, Cx43
staining in the membrane and cytoplasm was increased
in all astrocytes (Fig. 2a, HIV-tat, 24 h). qRT-PCR ana-
lysis for Cx43 and GAPDH mRNA demonstrated that
HIV-tat upregulates Cx43 mRNA up to ~sixfold as com-
pared to untreated cells (Fig. 2b, *p ≤ 0.002 at all-time
points analyzed). Western blot analysis of these samples
indicated that HIV-tat treatment increased Cx43 protein
6 to 48 h post treatment (Fig. 2c at all-time points ana-
lyzed, p ≤ 2.3 × 10−5). Tubulin was used as a loading con-
trol (Fig. 2c, tub).
To examine the function of these channels, dye
coupling was performed. In control conditions, astro-
cytes were 100 % coupled to other surrounding astro-
cytes (data not shown) with an average of 10 ± 2.6
cells coupled for each cell microinjected with LY
(Fig. 2d, dye coupling index). HIV-tat treatment of
human astrocytes increased the numbers of coupled
cells up to 27.3 ± 4.76 cells per microinjection (Fig. 2d,
*p < 0.003), suggesting that toxic signals generated in
a few HIV-infected astrocytes could reach longer dis-
tances by a HIV-tat-dependent mechanism.
Furthermore, HIV-tat effects on Cx43 expression and
gap junctional communication were specific to human
cells, because treatment of mouse astrocytes with HIV-
tat (100 ng/ml) for 6 to 72 h did not alter Cx43
Fig. 3 HIV-tat did not increase Cx30 and mRNA protein expression and did not contribute to the enhanced gap junctional
communication induced by HIV-tat in human primary astrocytes. Human primary astrocytes were treated with recombinant HIV-tat protein
(100 ng/ml), and expression and function of Cx30-containing channels were analyzed. a Labeling for nuclei (DAPI, blue staining), Cx30
(Alexa 488, green staining), and GFAP (Cy3, red staining) in untreated conditions (control) and after 24 h HIV-tat treatment. The last panel
represents the merge of all colors. Bar 75 μm. b qRT-PCR for Cx30 and GAPDH using untreated and HIV-tat-treated (24 h) cultures of
astrocytes. No significant differences in mRNA Cx30 expression were detected in control cells (white bars). HIV-tat treatment decreased
Cx30 mRNA expression in a time-dependent manner (#p ≤ 0.001, n = 4, black bars). c Western blot analysis of Cx30 protein expression in
control and HIV-tat-treated human astrocytes. Tubulin (tub) was used as a loading control. As a Cx30 positive control, mouse brain was
used (+). HIV-tat decreased Cx30 expression in a time-dependent manner (Fig. 2c). d To examine the contribution of Cx30 to the
increased gap junctional communication induced by HIV-tat, we reduced further the expression of Cx30 using siRNA. In this condition,
we reduced Cx30 by at least 80 %; however, no changes in dye coupling were observed, suggesting that Cx43 mediate most of the
communication (n = 4, p ≤ 0.005)
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expression or gap junctional communication, suggesting
that the effect is species specific, as is HIV infectivity
(data not shown).
HIV-tat protein downregulates Cx30 expression, while
Cx30 does not contribute to the increased coupling index
observed after HIV-tat treatment
To determine whether HIV-tat also regulates expres-
sion of Cx30, human primary cultures of astrocytes
were treated with HIV-tat (1, 100, or 300 ng/ml), and
expression and localization of Cx30 was examined as
described for Cx43. Our data indicate that HIV-tat
downregulates Cx30 in human astrocytes as demon-
strated by immunofluorescence (Fig. 3a), qRT-PCR
(Fig. 3b), and western blotting (Fig. 3c). Despite the
downregulation of Cx30 by HIV-tat, protein expres-
sion is significant. Thus, to determine whether the
low levels of Cx30 after HIV-tat treatment contribute
to the increased gap junctional communication in-
duced by HIV-tat , Cx30 siRNA was transfected into
primary cultures of human astrocytes using Lipofecta-
mine 2000, and gap junctional communication was
determined as described above. Cx30 siRNA reduced
Cx30 protein expression in 78.7 ± 12.65 % instead of
9 to 28 % observed with just HIV-tat (Fig. 3 and
Table 2). Despite the reduction of Cx30 protein by the
combination of HIV-tat and Cx30 siRNA treatment
(Fig. 3d), we still detected a significant increase in coupling
index, indicating that HIV-tat mainly targets Cx43 and that
increased gap junctional communication in response to
HIV-tat treatment is mediated by Cx43-containing
channels.
HIV-tat binds to the Cx43 promoter, but not to the Cx30
promoter
The main function of HIV-tat protein in the HIV cell
cycle is to enhance and stabilize Pol II transcription of
the viral DNA. HIV-tat binds to the RNA stem-loop
structure, the trans-activating response (TAR) element,
found at the 5′ ends of nascent HIV transcripts. HIV-
tat’s binding to TAR alters the formation of the tran-
scription complex and recruits the transcription factor
P-TEFb of CDK9 and cyclin T1, to increase the produc-
tion of full length viral RNA [28, 29]. However, it was
unknown whether HIV-tat binds and affects Cx43
promoter activity.
Human primary astrocytes were transfected with HIV-
tat-FLAG for 24 h, and ChIP analysis was performed to
demonstrate binding of HIV-tat-FLAG to the Cx43 pro-
moter as shown in Fig. 4a, b (n = 4). HIV-tat-FLAG
immunoprecipitation pulls down the Cx43 promoter
(see amplification curves of Cx43 DNA, tat-FLAG),
demonstrating that HIV-tat-FLAG binds to this pro-
moter (Fig. 4b, ChIP Cx43 tat-FLAG). No binding of
HIV-tat-FLAG to the Cx43 promoter was detected with
any negative controls, including an irrelevant isotype-IgG
matched, or untransfected cells (Fig. 4b, IgG and non-
transfected). In agreement with our data that HIV-tat did
not increase Cx30 expression, ChIP analysis of the Cx30
promoter did not show any binding (Fig. 4b, ChIP Cx30).
These data indicate that HIV-tat increases expression of
Cx43, but not Cx30, by a mechanism that involves in-
creased HIV-tat’s binding to the Cx43 promoter, Cx43
mRNA production, protein synthesis, and gap junctional
communication. We propose that HIV-tat is an early viral
factor and enables HIV-infected cells to maintain Cx43
Fig. 4 HIV-tat binds to the Cx43 promoter, but not to the Cx30 promoter, in human primary astrocytes. Human primary astrocytes were transfected
with pcDNA3.1+/tat101-flag, and binding of this HIV protein to the Cx43 and Cx30 promoter was assayed by ChIP. a Representative PCR curves of
Cx43 promoter DNA amplification after 24 h of HIV-tat-FLAG transfection and subsequent ChIP. In the plot, amplification of input, tat-FLAG, irrelevant
IgG, and non-transfected are shown. b Compilation of four ChIP experiments. Primary astrocytes were transfected with HIV-tat-FLAG to
examine its binding to the Cx43 promoter using ChIP. Negative controls for the ChIP using IgG, or non-transfected astrocytes (data not
shown) did not show significant amplification. Only HIV-tat-FLAG amplify and increase the binding at least 15-fold as compared to the
input amplification (B, ChIP Cx30). ChIP analysis for Cx30 like that for Cx43 showed no HIV-tat-FLAG binding to the Cx30 promoter
(n = 4, p = 0.004)
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expression, resulting in increased gap junctional communi-
cation between the few HIV-infected astrocytes and the
surrounding uninfected cells, enabling spread of toxic
signals.
Discussion
In this report, we demonstrate that HIV-tat, the transac-
tivator of the virus, binds to the Cx43 promoter and in-
creases Cx43 mRNA, protein, and gap junctional
communication. Thus, HIV-tat not only regulates HIV
transcription but also regulates an important host gene
within the CNS. Our published data demonstrate that
the maintenance or increase of Cx43 and gap junctional
communication as well as increased hemichannel open-
ing are essential to mediate bystander apoptosis between
the few infected astrocytes (4.7 ± 2.8 % in vitro and 8.2 ±
3.9 % in vivo using an SIV model) and neighboring unin-
fected cells such as uninfected astrocytes, neurons, and
brain endothelial cells [5, 7, 8, 25]. Our previous studies
also demonstrated that maintenance of gap junctional
communication by HIV infection enables intracellular
toxic signals, including cytochrome C-related signals
(cytochrome C cannot cross gap junctions due to its
size), IP3, and calcium generated in a few HIV-infected
astrocytes to spread to uninfected communicated cells
resulting in amplification of apoptosis and inflammation.
All of these changes are independent of active HIV repli-
cation. Thus, bystander damage is associated with infec-
tion, but not with replication, as HIV-tat is produced by
HIV-infected cells even in the presence of anti-retrovirals
[30, 31]. This may be an important mechanism mediating
HIV CNS damage despite inefficient HIV-infected cells or
replication.
Our data reflect the current status of the majority of
people infected with HIV, where HIV replication is min-
imal due to successful antiretroviral treatment. However,
despite low replication and normal CD4 counts, 50–70 %
of the HIV-infected population shows some signs of
cognitive impairment [32, 33]. Thus, it is not the virus
mediating these effects; it is more likely that these are
amplification systems altered by viral factors that are not
impacted by antiretroviral treatment. Currently, antiretro-
viral treatments have no effect on HIV-tat production.
Thus, this protein is produced and secreted independently
of effective viral replication [31], suggesting that the ef-
fects observed in HIV-infected astrocytes could be present
in HIV-infected individuals regardless of successful com-
bination antiretroviral therapy (cART). In addition to the
effects of HIV-tat on gap junctional communication, this
HIV protein is also directly neurotoxic, capable of trigger-
ing inflammation and altering several synaptic compo-
nents [13, 34, 35].
Our data and that of others have demonstrated a
key role of astrocytes in the pathogenesis of Neu-
roAIDS by mechanisms that involve gap junctional
communication, hemichannels, and Wnt pathways
[11, 25, 36–39]. Thus, we propose that HIV-tat upre-
gulates Cx-containing channels, including gap junc-
tions and hemichannels, to spread toxic signals into
neighboring cells by increasing the radius of diffusion
of intracellular factors through gap junctions.
Normally, gap junctions are master regulators of elec-
trical and metabolic coordination in most tissues includ-
ing the CNS. It has recently become evident that
connexin-containing channels, gap junctions and hemi-
channels, are also key regulators of learning and mem-
ory, long-term potentiation, and depression; the ratio of
NR2a/NR2b; and electrical oscillations [40–45]. Thus,
any changes in gap junctional communication or Cx
expression will affect CNS function, as observed in HIV-
infected individuals. These channels in parenchymal
cells are shut down in response to inflammatory stimuli
such as cytokines, chemokines, and pathogens [4, 5, 46].
However, HIV infection of astrocytes has a different
effect, in that connexin-containing channels are main-
tained or increased, resulting in bystander apoptosis of
Fig. 5 Schematic representation of our working model. We believe HIV infects a small population of astrocytes, inducing the expression of HIV-tat
and subsequent upregulation of expression of Cx43. This upregulation of Cx43 expression results in the maintenance of gap junctional communication
and opening of Cx43 hemichannels on the surface of the astrocytes. Both Cx43-containing channels, GJ and hemichannels, enable toxic intracellular
signals (probably IP3 and calcium related) to spread into uninfected neighboring cells resulting in apoptosis. In contrast, HIV-infected astrocytes survive
apoptosis, generating CNS reservoirs
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uninfected cells. In agreement, some reports indicate
that functional gap junction channels may help to amp-
lify ischemic damage by enhancing the propagation of
pro-apoptotic death signals between dying and healthy
cells [47]. Additionally, α-particle-irradiated cells also
transmit pro-apoptotic signals through gap junctions to
non-irradiated cells [48]. These results suggest that gap
junction channels can be used to spread damage into
healthy areas.
Direct binding of HIV-tat to the Cx43 promoter was
unexpected. The promoters for Cxs and long-term re-
peats (LTR) of HIV are very different and share the use
of few transcription factors. The human Cx43 promoter
contains several putative transcription factor binding
sites including AP-1, AP-2, cAMP response elements,
Ets, specificity protein-1 consensus sites, several se-
quences resembling half the palindromic estrogen
response elements and progesterone response elements,
and an activator and a repressor site that have been
functionally characterized in the mouse gene [23, 49, 50].
There are no current elements shared by the virus and
the Cx43 promoter that enable binding of Pol II in
similar sites. HIV transcription requires the transcrip-
tion factors TFIID, SP1, NF-KB, NFAT, and AP-1, and
upstream also contains USF, Ets, and LEF-1 binding
sites [51]. Interestingly, we did not observe that HIV-
tat increased Cx43 expression in mouse astrocytes,
suggesting that HIV-tat effects are human DNA spe-
cific, similar to HIV infection. This may be due to the
expression of cyclin T1, a human-specific protein. To
characterize these differences, further studies are re-
quired to identify the areas of binding of Pol II to the
Cx43 promoter, transcription factors, and how HIV-tat
regulates these interactions.
Furthermore, HIV-tat binding to the Cx43 promoter
was specific, because no binding was detected to the
Cx30 promoter. Currently, there are few reports describ-
ing the sequences and binding sites in this promoter. It
is known that Cx30 transcription can start in different
exons, for example, in the epidermis, transcription be-
gins in exon 1, but in the CNS, it starts in exon 3. In the
promoter region of the Cx30 human gene, upstream of
exon 1, a TATA motif, several potential binding sites for
sp1, and a consensus sequence for early growth response
gene products (Egr)-binding are present [24]. However,
any similarities or differences in the promoter need fur-
ther description to identify the differences in HIV-tat
sensitivity.
Our results suggest that blocking secretion or pro-
duction of HIV-tat within the CNS or reducing gap
junctional communication to physiological levels is a
novel potential therapeutic approach to reduce the
ongoing CNS compromise observed in a large popula-
tion of HIV-infected individuals.
Conclusions
The main conclusion of our work is that HIV-tat upre-
gulates expression of Cx43 and maintains functional gap
junctional communication by direct binding or inter-
action to the Connexin43 promoter. This upregulation
of Cx43-containing channels allows toxic signals gener-
ated in few HIV-infected astrocytes to spread into unin-
fected cells by a gap junction or hemichannel- dependent
mechanism resulting in bystander apoptosis of CNS cells
(see summary in Fig. 5).
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